Qian X, Dougall W C, Hellman M E, Greene M I
Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia 19104-6082.
Oncogene. 1994 May;9(5):1507-14.
p185c-neu and epidermal growth factor receptor (EGFR) associate into an active heterodimer, and overexpression of these two receptors leads to a transformed phenotype. However, the association of EGFR and kinase-deficient Neu proteins (point mutant N757 or cytoplasmic domain deletion mutant N691stop) results in a defective or inactive heterodimeric complex. In this report we explore the biological consequences of heterodimerization between EGFR and wild-type (WT) or kinase-deficient mutant Neu proteins in living cells. We show that co-expression of EGFR and kinase-deficient Neu proteins abolished the synergistic transformation and tumorigenicity. Moreover, the normal responses of EGFR to ligand were significantly suppressed, e.g., loss of EGF-dependent transformation, reduced rate of receptor endocytosis and turnover, diminished DNA synthesis, and decreased EGF binding affinity. These results provide the first evidence that kinase-deficient Neu proteins suppress normal EGFR function and display a dominant negative mutant phenotype. Together with the stimulatory effects observed in cells forming active heterodimers, these studies provide a role for heterodimerization of EGFR and Neu/c-erbB2 in interreceptor activation and synergistic signaling which may be responsible for the transition from normal receptor function into oncogenesis.
p185c-neu与表皮生长因子受体(EGFR)形成活性异二聚体,这两种受体的过表达会导致转化表型。然而,EGFR与激酶缺陷型Neu蛋白(点突变体N757或胞质结构域缺失突变体N691stop)的结合会形成有缺陷或无活性的异二聚体复合物。在本报告中,我们探讨了活细胞中EGFR与野生型(WT)或激酶缺陷型突变体Neu蛋白之间异二聚化的生物学后果。我们发现,EGFR与激酶缺陷型Neu蛋白的共表达消除了协同转化和致瘤性。此外,EGFR对配体的正常反应受到显著抑制,例如,丧失EGF依赖性转化、受体胞吞作用和周转速率降低、DNA合成减少以及EGF结合亲和力下降。这些结果首次证明激酶缺陷型Neu蛋白可抑制正常EGFR功能并表现出显性负突变表型。与在形成活性异二聚体的细胞中观察到的刺激作用一起,这些研究揭示了EGFR与Neu/c-erbB2异二聚化在受体间激活和协同信号传导中的作用,这可能是导致从正常受体功能转变为肿瘤发生的原因。